Literature DB >> 33638688

Assessment of localization accuracy and postsurgical prediction of simultaneous 18F-FDG PET/MRI in refractory epilepsy patients.

Kun Guo1, Bixiao Cui1, Kun Shang1, Yaqin Hou1, Xiaotong Fan2, Hongwei Yang1, Guoguang Zhao2, Jie Lu3,4,5.   

Abstract

OBJECTIVES: To evaluate the accuracies of simultaneous 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging ([18F]-FDG PET/MRI) in preoperative localization and the postsurgical prediction.
METHODS: This retrospective study was performed on ninety-eight patients diagnosed with refractory epilepsy whose presurgical evaluation included [18F]-FDG PET/MRI, with 1-year post-surgery follow-up between August 2016 and December 2018. PET/MRI images were interpreted by two radiologists and a nuclear medicine physician to localize the EOZ using standard visual analysis and asymmetry index based on standard uptake value (SUV). The localization accuracy and predictive performance of simultaneous 18F-FDG PET/MRI based on the surgial pathology and postsurgical outcome were evaluated.
RESULTS: A total of 41.8% (41/98) patients were found to have a definitely structural abnormality on the MR portion of PET/MRI; 93.9% (92/98) were shown hypometabolism on the PET portion of the hybrid PET/MRI. PET/MRI identified 18 cases with subtle structural abnormalities on MRI re-read. Six percent (6/98) of patients PET/MRI were negative. A total of 65.3% (64/98) patients showed seizure-free at 1-year follow-up after epilepsy surgery. The sensitivity, specificity, and accuracy of [18F]-FDG PET/MRI was 95.3%, 8.8%, and 65.3% for seizure onset localization based on surgical pathology and postsurgical outcome, respectively. Multivariate regression analysis indicated that concordant of EOZ localization between PET/MRI and surgical resection range, which was a good positive predictor of seizure freedom (Engel I) (OR = 14.741, 95% CI 3.934-55.033, p < 0.001).
CONCLUSIONS: [18F]-FDG PET/MRI used as two combined modalities providing additional sensitivity when detecting possible epileptic foci and will probably improve the surgical outcome. KEY POINTS: • Sensitivity, specificity, and accuracy of [18F]-FDG PET/MRI were 95.3%, 8.8%, and 65.3% for seizure onset localization based on surgical pathology and postsurgical outcome, respectively. • Concordance of EOZ localization between PET/MRI and surgical resection range was a good positive predictor of seizure freedom; presurgical [18F]-FDG PET/MRI will probably improve the surgical outcome.

Entities:  

Keywords:  Epilepsy; Magnetic resonance imaging; Positron emission tomography; Prognosis; Surgery

Year:  2021        PMID: 33638688     DOI: 10.1007/s00330-021-07738-8

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  17 in total

Review 1.  Current status and future role of brain PET/MRI in clinical and research settings.

Authors:  P Werner; H Barthel; A Drzezga; O Sabri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-09       Impact factor: 9.236

2.  Subsequent experience in hybrid PET-MRI for evaluation of refractory focal onset epilepsy.

Authors:  Jorge Daniel Oldan; Hae Won Shin; Amir Hossein Khandani; Carlos Zamora; Thad Benefield; Valerie Jewells
Journal:  Seizure       Date:  2018-08-01       Impact factor: 3.184

3.  The predictive value of hypometabolism in focal epilepsy: a prospective study in surgical candidates.

Authors:  José Tomás; Francesca Pittau; Alexander Hammers; Sandrine Bouvard; Fabienne Picard; Maria Isabel Vargas; Francisco Sales; Margitta Seeck; Valentina Garibotto
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-05-29       Impact factor: 9.236

4.  FDG-PET improves surgical outcome in negative MRI Taylor-type focal cortical dysplasias.

Authors:  F Chassoux; S Rodrigo; F Semah; F Beuvon; E Landre; B Devaux; B Turak; C Mellerio; J-F Meder; F-X Roux; C Daumas-Duport; P Merlet; O Dulac; C Chiron
Journal:  Neurology       Date:  2010-12-14       Impact factor: 9.910

5.  The utility of 18F-fluorodeoxyglucose PET (FDG PET) in epilepsy surgery.

Authors:  Chaturbhuj Rathore; John C Dickson; Rute Teotónio; Peter Ell; John S Duncan
Journal:  Epilepsy Res       Date:  2014-07-07       Impact factor: 3.045

6.  Surgical outcome in PET-positive, MRI-negative patients with temporal lobe epilepsy.

Authors:  Carla LoPinto-Khoury; Michael R Sperling; Christopher Skidmore; Maromi Nei; James Evans; Ashwini Sharan; Scott Mintzer
Journal:  Epilepsia       Date:  2011-12-22       Impact factor: 5.864

7.  Seizure outcome of pediatric epilepsy surgery: Systematic review and meta-analyses.

Authors:  Elysa Widjaja; Puneet Jain; Lindsay Demoe; Astrid Guttmann; George Tomlinson; Beate Sander
Journal:  Neurology       Date:  2020-01-29       Impact factor: 9.910

Review 8.  Adult epilepsy.

Authors:  John S Duncan; Josemir W Sander; Sanjay M Sisodiya; Matthew C Walker
Journal:  Lancet       Date:  2006-04-01       Impact factor: 79.321

9.  MRI-negative PET-positive temporal lobe epilepsy: a distinct surgically remediable syndrome.

Authors:  R P Carne; T J O'Brien; C J Kilpatrick; L R MacGregor; R J Hicks; M A Murphy; S C Bowden; A H Kaye; M J Cook
Journal:  Brain       Date:  2004-07-28       Impact factor: 13.501

Review 10.  Outcomes of epilepsy surgery in adults and children.

Authors:  Susan Spencer; Linda Huh
Journal:  Lancet Neurol       Date:  2008-06       Impact factor: 44.182

View more
  2 in total

1.  [18F]FDG PET/MRI and magnetoencephalography may improve presurgical localization of temporal lobe epilepsy.

Authors:  Kun Guo; Jingjuan Wang; Bixiao Cui; Yihe Wang; Yaqin Hou; Guoguang Zhao; Jie Lu
Journal:  Eur Radiol       Date:  2021-10-14       Impact factor: 5.315

2.  Combined quantitative T2 mapping and [18F]FDG PET could improve lateralization of mesial temporal lobe epilepsy.

Authors:  Miao Zhang; Hui Huang; Wei Liu; Lihong Tang; Qikang Li; Jia Wang; Xinyun Huang; Xiaozhu Lin; Hongping Meng; Jin Wang; Shikun Zhan; Biao Li; Jie Luo
Journal:  Eur Radiol       Date:  2022-03-28       Impact factor: 7.034

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.